​Pathology - Chronic Myelogenous Leukemia (CML)

​Pathology - Chronic Myelogenous Leukemia (CML)
The Philadelphia chromosome t9;22 is linked to the formation of a hybrid gene ber-abl, which encodes a protein with tyrosine kinase activity.
Most commonly observed in individuals of middle age.

Study of the nature and causes of diseases. 
Bone marrow: Hypercellular: elevated levels of myeloid progenitor cells
Peripheral blood smear reveals leukocytosis characterized by a combination of fully developed and undeveloped myeloid cells.

Presenting Symptoms 
The patient has symptoms of low-grade fever, tiredness, nocturnal sweats, and splenomegaly. Laboratory results indicate: The patient exhibits leukocytosis, namely an increase in neutrophils and metamyelocytes. The leukocyte alkaline phosphatase (LAP) is lowered, but the serum B levels are up. Additionally, there is hyperuricemia. 

The treatment regimen includes chemotherapy with hydroxyurea and amatinib, a tyrosine kinase inhibitor, as well as bone marrow therapy.
Death typically arises as a result of the transition into acute myeloid leukemia (blast crisis).
Chronic myelogenous leukemia (CML) is classified as a myeloproliferative condition, which includes polycythemia vera, essential thrombocythemia, and myelofibrosis.